Toxicity associated with in vivo administration of adenovirus (Ad) vectors has been linked to activation of both innate and adaptive immune responses. Pre-existing immunity to the prevalent Ad serotypes, acquired by the majority of the human population as a result of natural infections, has the potential to modulate vector efficacy and safety. Previously, we evaluated some aspects of toxicity from systemic Ad vector in vector-naïve and pre-immunized rhesus monkeys. In this report, we summarize data from several studies analyzing toxic effects from systemically administered E1/E3-deleted Ad vector in vector-naïve and pre-immunized C57BL/6 mice. Our results indicate that pre-immunization can be associated with increased mortality shortly after systemic administration of Ad. Transient leukopenia and thrombocytopenia were observed early post vector infusion in both vector-naïve and pre-immunized animals. Preexposure to the vector did not prevent induction of proinflammatory cytokines; however, pre-immunized mice showed less tissue toxicity. Growth of bone marrow myeloid and erythroid progenitors was transiently inhibited in preimmunized animals, but only the myeloid progenitors were affected in vector-naïve animals. In summary, pre-existing immunity to Ad vector substantially modifies host immune responses to systemic Ad vector.
Introduction
Adenovirus (Ad) vectors have been considered in many gene therapy applications. 1, 2 In vivo administration of Ad vectors is usually associated with dose-dependent toxicity that has been linked to activation of both innate and adaptive immune responses. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Systemically administered Ad vector is efficiently distributed to different tissues, [13] [14] [15] [16] exerting its effects both locally and systemically.
Due to a high frequency of naturally occurring Ad infections, 17 most humans carry anti-Ad antibodies, a significant proportion of which are capable of virus neutralization. [18] [19] [20] Previous reports showed that efficiency of gene transfer with Ad vectors, based on prevalent human serotypes such as serotypes 2 and 5, can be substantially compromised in individuals with pre-existing immunity. 13, 16, 21 In this report, we summarize data from several studies analyzing toxic effects from high-dose systemically administered first-generation Ad (human serotype 5) vector in C57BL/6 mice. Evaluation parameters included hematological counts, serum levels of hepatic enzymes, histopathology, serum cytokine levels and bone marrow progenitor cell growth. These parameters were assessed in both vector-naïve and pre-immunized animals to address the effect of pre-existing anti-Ad immunity on vector-induced systemic toxicity. We found that, despite the reduced signs of tissue toxicity in pre-immunized animals compared to those in vector-naïve animals, the presence of pre-existing anti-vector immunity was associated with increased mortality following systemic vector infusion.
Results
The goal of the present studies was to evaluate in mice the impact of pre-existing immunity on host responses to systemically administered first-generation (E1/E3-deleted) human serotype 5 Ad vector. To monitor vectormediated gene expression, the construct used in the described work carried a cassette expressing jellyfishderived green fluorescent protein (GFP), thus named Adhu5-GFP. As shown in Table 1 , the studies contained four animal groups: (1) Control, injected with phosphate-buffered saline (PBS); (2) Immunized Control (Imm-Control), immunized intramuscular (i.m.) with Adhu5-GFP vector and 28 days later injected i.v. with PBS; (3) Naïve, injected intravenous (i.v.) with Adhu5-GFP vector without prior immunization; and (4) Pre-immunized (Pre-imm.), immunized i.m. with Adhu5-GFP vector and 28 days later injected i.v. with the same vector. In some described studies, group 2 (Imm-Control) was omitted.
Immunological sensitization to the vector by i.m. immunization was confirmed by assessing anti-vector neutralizing and total IgG antibodies in the mouse sera. The titers of anti-Ad neutralizing antibodies in immunized mice varied from 1/40 to 1/320 (refer to Materials and methods for experimental details), and in mice administered with 1 Â 10 11 viral particles (vp) averaged at 1/240 (data not shown). The levels of the total IgG antibodies increased as the immunizing dose of vector was increased, and were not detected in control or naïve groups ( Figure 3a ). As expected, 10, 16 vector-mediated tissue transduction was reduced in the pre-immunized animals, based on analysis of GFP expression in the liver and spleen (data not shown).
Hematology, serum transaminase and histopathology analyses
Whole blood samples were collected at different time points after i.v. vector injection, and various hematological parameters, including cell blood counts and differential counts, were evaluated. Similar to our previously reported observations in rhesus monkeys, 15, 16 high-dose systemic Ad vector administration led to transient leukopenia and thrombocytopenia, or reduction in number of white blood cells (WBC) and platelets in peripheral circulation, respectively ( Figure 1 ). Prior to a decrease in WBC concentration, a short-term increase was apparent immediately after vector injection (see data for 1 h, Figure 1a ), presumably resulting from enhanced mobilization of cells from bone marrow in response to vector-induced inflammation. The extent of leukopenia was similar for vector-naïve and pre-immunized animals, and cell counts were completely restored by day 5 post vector ( Figure 1a ). Similar kinetics were observed for different WBC fractions (data not shown). Thrombocytopenia was slightly more prolonged than leukopenia (Figure 1b) . Moreover, thrombocytopenia persisted longer in vector-naïve animals; platelets in naïve mice returned to the baseline approximately 2 weeks post vector (data not shown), whereas in mice pre-immunized with 1 Â 10 11 vp of vector, platelets returned to normal by day 5 post vector ( Figure 1b) . Thus, the recovery from thrombocytopenia appeared to correlate with the level of anti-vector immunity.
Consistent with systemic Ad vector targeting the liver, an elevation of hepatic enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT), or transaminases, in mouse sera was observed (Figure 2 ). Significant increases in serum transaminases were apparent approximately 1 day post vector injection for both vector-naïve and pre-immunized groups. In preimmunized animals, transaminases returned to the baselines (those of the Control groups) by day 2 post vector ( Figure 2 ). In vector-naïve animals, the elevation of transaminases persisted over 2 weeks post vector, peaking at day 5. When different levels of anti-vector immunity were induced by immunizing with different doses of vector (Figure 3a) , mice with higher prior titers of anti-vector antibodies showed smaller elevation in serum transaminases following i.v. injection of 2 Â 10 11 vp of vector ( Figure 3b ). These results indicate two components to liver toxicity. The first is seen shortly after vector administration (to approximately 1 day post vector) and appears not to be related to transduction or affected by pre-existing immunity, while the second is delayed and only observed in naïve animals.
Histopathology was assessed following i.v. vector injection in a number of tissues, including heart, kidney, liver, lung, spleen and bone marrow (data not shown). No significant differences were observed between vectornaïve and pre-immunized groups in the first 2 days post vector. Some pathology signs, including inflammatory infiltrates and signs of apoptosis, were observed in the liver at days 3 to 5 post vector, which were more profound in naïve compared to pre-immunized animals.
Evaluation of serum cytokines
The induction of serum cytokines was evaluated at different time points post i.v. injection with 2 Â 10 11 vp/ mouse of Adhu5-GFP vector, using Luminex-100 multiplex technology as well as commercial enzyme-linked immunosorbent assay (ELISA) kits (Figure 4 
Effect of systemic Ad vector administration on bone marrow
As systemically infused Ad vector can efficiently distribute to different tissues, [13] [14] [15] [16] we were interested if it would have a direct pathological effect on bone marrow. We first evaluated the growth of bone marrow progenitors following i.v. injection with 2 Â 10 11 vp/ mouse of Adhu5-GFP vector in naïve and pre-immunized mice. The mouse bone marrow cells were cultured in a specialized methylcellulose medium allowing growth of myeloid and erythroid progenitor cells into colonies that could be distinguished morphologically ( Figure 5 ). For both naïve and pre-immunized groups, transient inhibition of myeloid progenitors (colonyforming unit of granulocyte-macrophage (CFU-GM)) was observed, and the levels were completely normalized by week 2 post vector, although the extent of CFU-GM inhibition was more profound in naïve animals. In addition, early short-term growth inhibition of erythroid progenitor (burst-forming unit of erythroid (BFU-E)) was observed only in pre-immunized animals.
To assess the effect of systemic Ad vector on populations of precursor cells developed in the bone marrow, we evaluated bone marrow histopathology from paraffin-embedded sections. Significant pathological signs, including histiocyte (macrophage) infiltration, serous degeneration, apoptosis (Figure 6a ), as well as markedly reduced cellularity (Figure 6b ), were seen in naïve animals. These pathological signs were most apparent up to day 5 post vector and subsided by day 15. In contrast, pathological signs were practically absent in pre-immunized animals at all analyzed time points. From hematoxylin and eosin (H&E) and periodic acidSchiff stained sections, the ratios of myeloid to erythroid (M:E) were determined. A significant reduction in M:E ratio was observed in naïve but not pre-immunized animals ( Figure 6c ). These results indicate that preexisting immunity exerts some protection against bone Pre-existing immunity leads to increased mortality in mice AN Varnavski et al marrow tissue destruction, and an immunity-dependent mechanism exists to transiently inhibit erythroid progenitor growth.
Increased mortality of pre-immunized mice following systemic vector administration An intriguing observation was an increased mortality of the pre-immunized animals following i.v. Ad vector injection (Table 2) . A similar finding was recorded when Ad vector-immunized mice with induced mammary tumors were intratumorally injected with high-dose Ad vector. 21 Based on several studies in our laboratory, tail vein injection of 2 Â 10 11 vp of Adhu5-GFP vector was rarely lethal to 10-12-week-old vector-naïve C57BL/6 mice (no naïve mice died in four therein described studies). In contrast, when the same dose of Adhu5-GFP vector was i.v. delivered to 10-12-week-old C57BL/6 mice pre-immunized i.m. with 1 Â 10 11 vp of the same vector, 11-40% of mice died within 24 h following i.v. injection. Some animals died within the first hour post i.v. vector administration, while others within several hours of injection (refer to legend to Table 2 ). The data were analyzed using the Pearson w 2 test, showing a significant difference (P-value o0.05) between the groups in two out of four independent studies. When the data from all four studies were combined, based on the fact that all the studies were conducted under the same experimental conditions, the test significance was further increased. Noticeably, all the animals immunized with 1 Â 10 10 or 1 Â 10 11 vp of the vector developed antivector neutralizing antibodies (data not shown), although the titers of these antibodies varied and did not appear to correlate with subsequent death of the animal.
Discussion
Toxicity associated with in vivo administration of Ad vector has been linked to activation of both innate and adaptive immune responses. Pre-existing immunity leads to increased mortality in mice AN Varnavski et al administered Ad vector has been shown to efficiently distribute to different tissues, [13] [14] [15] [16] exerting its affects locally and systemically. Tissue damage associated with inflammation at the site of vector deposition has been partially attributed to activation of vector productspecific cytotoxic T-lymphocytes. [22] [23] [24] In this report, we presented results of several studies analyzing features of systemic toxicity resulting from i.v. administration of high-dose Ad vector in vector-naïve and pre-immunized C57BL/6 mice.
Confirming our previous findings in rhesus monkeys, 15, 16 systemic Ad vector induced transient leukopenia and thrombocytopenia. Decreases in circulating platelets, correlated with previously reported signs of coagulopathy in non-human primates, 15, 16, 25 were more prolonged in vector-naïve compared to pre-immunized animals.
Greater elevations of serum transaminases and more profound signs of liver histopathology in naïve compared to those in pre-immunized animals indicated that pre-existing immunity had a protective effect against tissue toxicity. These findings are in agreement with previous reports. 13, 16 An exception was a recently published study showing increased histopathology in Table 1 for group description. Mice from Imm-Control and Pre-imm. groups were immunized i.m. with 1x10 11 vp. Average values for IL-6, TNF-a, IL-2, IFN-g, IL-12p70 and MIP-2 cytokines in mouse peripheral blood at the indicated times post i.v. vector are shown, calculated from three to four animals per group. IL-6, TNF-a, IL-2 and IFN-g were measured using Luminex-100 System (Luminex Corporation, Austin, TX, USA) and Beadlyte Mouse Multi-Cytokine Detection System 2 (Upstate Biotechnology, Lake Placid, NY, USA). The results are presented as fluorescent units. IL-12p70 and MIP-2 were measured using IL-12p70 and MIP-2 ELISA kits (BioSource International, Camarillo, CA, USA), respectively. The error bars represent one standard deviation from the mean values. These results are representative of two independent experiments. *Significant (Po0.05) by two-tailed unpaired Student's t-test, compared to the corresponding time point of the Control group.
Pre-existing immunity leads to increased mortality in mice AN Varnavski et al pre-immunized compared to naïve mice following intratumoral delivery of Ad vector. 21 Despite an apparent protective effect of pre-immunization on tissue-associated toxicity from systemic Ad vector, pre-immunization did not prevent systemic induction of pro-inflammatory cytokines. A significant distinction between mice and primates was systemic induction of TNF-a, observed in mice but not in primates. 14, 16 Previously, we found that systemic administration of high-dose Ad vector in non-human primates could inhibit the growth of bone marrow progenitor cells. 15, 16 In particular, inhibition of myeloid progenitor growth was observed in both vector-naïve and pre-immunized rhesus monkeys; however, the erythroid progenitor growth was affected only in pre-immunized monkeys. Similar results were obtained in C57BL/6 mice in the current studies. The growth of bone marrow myeloid progenitors was transiently inhibited in both vectornaïve and pre-immunized groups, with more profound effect in the vector-naïve animals, and a brief (for about 24 h) drop in erythroid progenitor growth seen only in pre-immunized animals. Although the underlined physiological mechanisms remain unclear, these results may indicate that similar pathways of Ad vector-mediated inhibition of bone marrow progenitor development exist in primates and rodents.
Following i.v. infusion of high-dose Ad vector, significant bone marrow histopathology was observed in vector-naïve animals and was virtually absent in preimmunized animals. Transient reductions in the relative number of myeloid cells (decrease in M:E ratio) in the naïve animals were consistent with an inhibition of myeloid progenitor growth. However, since the decrease in M:E ratio was apparent very early post vector infusion, other myeloid cells in the bone marrow could be affected. Interestingly, the M:E ratio was not noticeably changed in the pre-immunized animals. Considering that myeloid fraction is dominant in mouse bone marrow (M:EE20 for naive C57BL/6 mice), the effect on erythroid fraction could easily be unnoticed, and only a small elevation in M:E ratio could indicate a substantial reduction in erythroid fraction. It remains unclear what mechanisms contribute to the observed bone marrow abnormalities. One possibility is a direct effect of the vector transduction. Although the vector transduction of bone marrow cells was not evaluated in these studies, based on our previous observations in monkeys, [15] [16] this possibility alone is unlikely. Despite the apparent differences in bone marrow abnormalities between naïve and pre-immunized animals, the levels of systemic cytokines were similar. Further analysis of the local vector-induced cytokine environment (not analyzed here) may be useful. Pre-existing immunity leads to increased mortality in mice AN Varnavski et al An unexpected finding of these studies was increased mortality of pre-immunized animals following systemic infusion of high-dose Ad vector. A significant, but yet unclear, observation was that some animals died within the first hour post i.v. vector administration, while others died within several hours of injection, suggesting the possible involvement of a range of effector mechanisms. The fact that only a fraction of animals died and only after a high vector dose may indicate a threshold-like phenomenon. While the pathological pathways involved in the observed systemic toxicity remain a mystery, they apparently bypass direct tissue destruction (overall, signs of tissue-associated toxicity were less prominent in pre-immunized compared to naïve animals). The titers of developed anti-vector neutralizing antibodies varied between animals and did not seem to correlate with subsequent risk of mortality, although this should be confirmed in future studies.
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Interestingly, when rabbit IgG fraction of anti-Ad antibodies was passively transferred to mice, which was then followed by high-dose systemic Ad administration, not only did those mice show less tissue-associated pathology, but the mortality (from systemic Ad) was also reduced. 13 The action of rabbit IgG antibodies in mouse environment was restricted to antigen-specific Fabregion-mediated responses (such as virus neutralization), and did not fully reflect Fc-region-dependent responses (such as opsonization and anaphylaxis). Furthermore, that model did not address a possible involvement of other IgG antibody classes or vector-induced cytotoxic T-cell-mediated mechanisms.
In summary, mice pre-immunized i.m. with Ad vector showed less tissue toxicity upon systemic vector readministration. Pre-exposure to the vector, however, did not prevent from induction of pro-inflammatory cytokines. Growth of bone marrow myeloid progenitor cells was transiently inhibited by systemic Ad vector, and in the presence of anti-vector immunity the growth of erythroid progenitors was also transiently affected. Despite the reduced tissue-associated toxicity, vector pre-immunized animals were at a higher risk of mortality following high-dose systemic Ad vector administration. This was a consistent observation in four consecutive studies.
Materials and methods
Adenoviral vector
The E1/E3-deleted human serotype 5 Ad vector used in this study carried a cassette expressing jellyfish-derived GFP gene under the control of the cytomegalovirus (CMV) early promoter (Adhu5-GFP). The vector was prepared and evaluated for sterility, presence of endotoxin, viral particles per plaque-forming unit (PFU) ratio, presence of replication-competent adenovirus (RCA), and genome structure as described previously. 15, 26 All the vector preparations used in this study were sterile, endotoxin-free (o0.2 EU/ml and o0.02 EU/injection, based on LAL assay, Bio-Whittaker), correct by restriction endonuclease analysis of viral DNA, and contained less than 1 RCA in 10 7 vp. The particle-to-PFU ratios, determined in human embryonic kidney 293 cells ranged from 22 to 30.
Animals, vector administration and specimen collection
Female C57BL/6 mice, 6-8-week old, were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and maintained in the Animal Facility of the Wistar Institute. For i.m. immunization, mice from Imm-Control and Pre-imm. groups (see Table 1 ) were anesthetized with a solution of ketamine-xylazine (1.5 and 0.3 mg per mouse, respectively), small incisions were made to expose tibialis anterior muscles on both legs, and 5 Â 10 11 vp/ mouse in total). The incisions were closed with Vicryl suture. On day 28 (1 day prior to i.v. vector injection), mice were bled retro-orbitally to assess the levels of antivector neutralizing antibodies. The next day, mice from Naïve and Pre-imm. groups (Table 1) were injected with 2 Â 10 11 vp/mouse of Adhu5-GFP i.v. (tail vein) in 100-ml volume. Mice in Control and Imm-Control groups were injected with 100 ml of PBS. In some experiments, mice were bled retro-orbitally at 1 or 2 h post injection to assess hematology and blood chemistry parameters. Groups of mice were necropsied at different time points post vector administration for various analyses (as per Results).
At necropsy, mice were terminally bled by a cardiac puncture. Heart, kidney, liver, lungs, spleen and bone marrow were collected and fixed in 10% buffered formalin for histopathological evaluation. For bone marrow analysis, mouse hind legs were collected, and the femur and tibia bones were harvested by removing muscle tissue. One femur from each mouse was fixed in 10% buffered formalin for histopathology analysis. The rest of the bones were used for bone marrow cell isolation and methylcellulose culture (as described below).
Measurement of serum-neutralizing and total IgG antibody levels
The capacity of sera from pre-immunized mice to neutralize the infectivity of Adhu5-GFP vector was analyzed by assessing the ability of serum antibodies to inhibit vector transduction of human embryonic kidney 8431 cells, as described previously. 16, 27 GFP expression was assessed by FluoroImaging (Molecular Dynamics), Analysis of the combined data was performed on the basis that all four studies were conducted under the same experimental conditions.
Pre-existing immunity leads to increased mortality in mice AN Varnavski et al and neutralizing antibody titers were calculated using ImageQuant software (Molecular Dynamics) as serum dilution at which GFP fluorescence intensity was reduced by 50%. The levels of total anti-Ad IgG antibodies in vectorimmunized mice were evaluated using ELISA as follows. The wells of Costar high-protein-binding plates (Corning, NY, USA) were coated with 50 ml/well of 2 Â 10 10 vp/ml of Adhu5-GFP vector in PBS (pH 7.4) overnight at 41C. The vector solution was aspirated, and wells were washed three times with PBS (pH 7.4) containing 0.05% Tween-20. Plates were blocked with 200 ml/well of PBS containing 1% bovine serum albumin (BSA), 5% sucrose and 0.05% NaN 3 for 8 h at 41C. After aspiration and washing (as above), serial dilutions of tested mouse sera were added in 50 ml/well in PBS/1% BSA, and plates were incubated overnight at 41C. After aspiration and washing, 100 ml/well of 1/500 dilution of biotin-conjugated anti-mouse IgG antibody (Vector Laboratories, Burlingame, CA, USA) was added in PBS/ 1% BSA, and plates were incubated for 1 h at room temperature. Wells were aspirated, washed and 100 ml/well of 1/500 dilution of streptavidin-HRP (Vector Laboratories) was added for 30 min at room temperature. Wells were aspirated, washed and developed with 100 ml/well of TMB substrate. The reaction was stopped by addition of 100 ml of 2 M H 2 SO 4 , and relative values, corresponding to total anti-Ad IgG in tested mouse sera, were determined as OD 450 readings.
Histopathology analysis and gene expression
The collected tissues were fixed in 10% buffered formalin, embedded in paraffin and sectioned. Tissue sections (approximately 5-mm thick) were stained with H&E and analyzed by a certified pathologist from the Hospital of the University of Pennsylvania. The level of gene expression was evaluated qualitatively by monitoring GFP expression.
Hematology and serum transaminase evaluation
Small samples of whole blood were collected into 1.3-ml tubes containing potassium EDTA as anticoagulant (Sarstedt, Newton, NC, USA). Various hematological parameters, including cell blood counts and differentials, were measured for each sample using Hemavet 850 apparatus (CDC Technologies, Oxford, CT, USA).
Serum samples were prepared by allowing blood to coagulate and removing the clots by centrifugation. Serum AST and ALT levels were measured using ACE Clinical Chemistry System (Alfa Wassermann, West Caldwell, NJ, USA).
Measurement of serum cytokines
Levels of IL-6, TNF-a, IL-2 and IFN-g in mouse sera were evaluated using Luminex-100 System (Lyminex Corporation, Austin, TX, USA) and Beadlyte Mouse MultiCytokine Detection System 2 (Upstate Biotechnology, Lake Placid, NY, USA), as per manufacturer's recommendations. Mouse IL-12p70 and macrophage inflammatory protein (MIP)-2 were evaluated using the corresponding ELISA kits (BioSource International, Camarillo, CA, USA).
Methylcellulose culture and histological analysis of mouse bone marrow Bone marrow was flushed from the bones in Iscove's modified Dulbecco's medium (IMDM) containing 2% fetal bovine serum (FBS) using a 21G needle. To break cell aggregates, bone marrow pulp was pushed four to five times through the 21G needle. The cells were washed twice with the medium and resuspended in the M3434 medium (StemCell Technologies, Vancouver BC, Canada), supporting the growth of progenitor cell colonies. The cultures were prepared in 24-well plates in quadruplicate 0.5-ml aliquots and incubated at 371C in 5% CO 2 incubator. The numbers of burst-forming units of erythroid (BFU-E), CFU-GM and colony-forming units of granulocyte-erythrocyte-macrophage and megakaryocyte (CFU-GEMM) progenitor-derived colonies were determined at days 10-14 of culture under an inverted light microscope.
To evaluate bone marrow histopathology, mouse femurs were fixed in 10% buffered formalin for 48 h, decalcified in Cal-EX II decalcifying solution (Fisher Diagnostics, Fair Lawn, NJ, USA) for 48 h, embedded in paraffin and sectioned. The bone marrow 5-mm sections were stained with H&E as described previously, 15 or with periodic acid-Schiff (PAS) reagent as follows. After deparaffinization and hydration, the bone marrow sections were oxidized in 0.5% periodic acid solution (Sigma, St Louis, MO, USA) for 5 min, rinsed in distilled water, incubated in Schiff's reagent (Sigma) for 15 min, washed in tap water, counterstained in hematoxylin, washed in tap water, dehydrated and coverslipped. The slides were evaluated by a certified pathologist from the Hospital of the University of Pennsylvania.
Statistical analyses
The two-tailed unpaired Student's t-test was used to determine the significance of the hematology (Figure 1 ) and serum transaminase (Figure 2 ) results. The Pearson w
2 test was used to analyze mortality data ( Table 2 ).
